Clinical Trial Update: Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and efficacy of allogeneic mesenchymal stem cells in rapidly progressive interstitial lung disease, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Interstitial Pneumonia
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease

Drugs mentioned

• Allogeneic mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | Conditions: Idiopathic Interstitial Pneumonia, Interstitial Lung Disease | Phase 1, Phase 2 | Status: COMPLETED